| pubmed-article:9665011 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9665011 | lifeskim:mentions | umls-concept:C0686904 | lld:lifeskim |
| pubmed-article:9665011 | lifeskim:mentions | umls-concept:C0392756 | lld:lifeskim |
| pubmed-article:9665011 | lifeskim:mentions | umls-concept:C1707719 | lld:lifeskim |
| pubmed-article:9665011 | lifeskim:mentions | umls-concept:C0699603 | lld:lifeskim |
| pubmed-article:9665011 | lifeskim:mentions | umls-concept:C0699604 | lld:lifeskim |
| pubmed-article:9665011 | pubmed:dateCreated | 1998-11-30 | lld:pubmed |
| pubmed-article:9665011 | pubmed:abstractText | In patients receiving cyclosporine A (CyA)-based immunosuppressive therapy, Ca2+ channel blockers (CCBs) prevent the development of CyA-related nephrotoxicity in which increased Ca2+ content plays an important role. We evaluated the dynamics of the intracellular (erythrocytes) and extracellular (plasma) Ca2+ levels and the influence of the CCB, Phenihydine, on this process during the conversion from Sandimmun (S) to Sandimmun Neoral (SN). Forty-two patients were enrolled. The conversion from S to SN normalized the elevated CA2+ level of erythrocytes in groups with Phenihydine (n = 20) and without Phenyhidine (n = 12) 4 weeks after the switch (P < 0.05); this level remained stable until the end of study. Therefore we suggest that the switch from S to SN is effective in reducing elevated intracellular Ca2+ levels. The decrease of Ca2+ content in erythrocytes was similar in all groups switched to SN (with or without Phenihydine). The last effect should be an important argument to focus the further long-term investigations on the ability of CCBs to act as cytoprotective and neophroprotective agents during immunosuppressive protocols with the new microemulsion formulation of CyA. | lld:pubmed |
| pubmed-article:9665011 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9665011 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9665011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9665011 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9665011 | pubmed:issn | 0934-0874 | lld:pubmed |
| pubmed-article:9665011 | pubmed:author | pubmed-author:PetterssonEE | lld:pubmed |
| pubmed-article:9665011 | pubmed:author | pubmed-author:RosentalRR | lld:pubmed |
| pubmed-article:9665011 | pubmed:author | pubmed-author:BabarykinDD | lld:pubmed |
| pubmed-article:9665011 | pubmed:author | pubmed-author:AmerikaDD | lld:pubmed |
| pubmed-article:9665011 | pubmed:author | pubmed-author:AdamsoneII | lld:pubmed |
| pubmed-article:9665011 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9665011 | pubmed:volume | 11 Suppl 1 | lld:pubmed |
| pubmed-article:9665011 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9665011 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9665011 | pubmed:pagination | S337-9 | lld:pubmed |
| pubmed-article:9665011 | pubmed:dateRevised | 2006-9-18 | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:meshHeading | pubmed-meshheading:9665011-... | lld:pubmed |
| pubmed-article:9665011 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9665011 | pubmed:articleTitle | Does the switch from sandimmun to Sandimmun neoral reduce patient need for Phenihydine? | lld:pubmed |
| pubmed-article:9665011 | pubmed:affiliation | Department of Transplantation, Medical Academy of Latvia, Riga, Latvia. | lld:pubmed |
| pubmed-article:9665011 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9665011 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9665011 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
